Skip to main content
SpringerLink
Log in

Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis

  • Review
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract

Background

Targeted anti-IL-1β therapy may be a valuable option for the management of gouty arthritis. The present meta-analysis has evaluated the effect of canakinumab, an anti-IL-1β monoclonal antibody in gouty arthritis.

Methods

A standard meta-analysis protocol was developed and after performing a comprehensive literature search in MEDLINE, Cochrane, and International Clinical Trial Registry Platform (ICTRP), reviewers assessed eligibility and extracted data from three relevant articles. A random-effects model was used to estimate the pooled effect size as the mean difference in Visual Analouge Scale (VAS) score, serum hsCRP, serum Amyloid A, and risk ratio for global assessment between the groups. Quality assessment was done using the risk of bias assessment tool and summary of findings was prepared using standard Cochrane methodology with GradePro GDT.

Results

Treatment with canakinumab showed a mean reduction of VAS score by 14.59 mm [95% CI − 19.42 to − 9.77], serum hsCRP by 15.36 mg/L [95% CI 1.62–29.11], serum Amyloid A by 67.18 mg/L [95% CI 17.06–117.31], and improvement in patient global assessment (RR = 1.478; 95% CI 1.29–1.67) and physician global assessment (RR = 1.44; 95% CI 1.28–1.61). The probability that future studies may have a mean difference in VAS score less than zero has been calculated to be 27.3% using a cumulative distribution function (CDF) calculator.

Conclusion

This meta-analysis shows the beneficial effect of canakinumab over triamcinolone by reducing VAS score, serum hsCRP, serum amyloid A, and improvement in global assessments in acute gouty arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S et al (2008) The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10:R67

    Article  Google Scholar 

  • Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403–2406

    PubMed  Google Scholar 

  • Balduzzi S, Rucker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153–160

    Article  Google Scholar 

  • Berger P, McConnell JP, Nunn M, Kornman KS, Sorrell J, Stephenson K et al (2002) C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine 17:171–174

    Article  CAS  Google Scholar 

  • Busso N, So A (2010) Mechanisms of inflammation in gout. Arthritis Res Ther 12:206

    Article  Google Scholar 

  • Chakraborty A, Van LM, Skerjanec A, Floch D, Klein UR, Krammer G, Sunkara G, Howard D (2013) Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. J Clin Pharmacol 53(12):1240–1251

    Article  CAS  Google Scholar 

  • Challa DNV, Crowson CS, Davis JM 3rd (2017) The patient global assessment of disease activity in rheumatoid arthritis: identification of underlying latent factors. Rheumatol Ther 4:201–208

    Article  Google Scholar 

  • Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E et al (2015) Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 22:335–343

    Article  CAS  Google Scholar 

  • Cumulative Distribution Function (CDF) (2020) Calculator for the t-Distribution [Software]. [Online]. https://www.danielsoper.com/statcalc

  • GRADEpro GDT (2015) GRADEpro Guideline Development Tool [Software]. [Online]. https://gradepro.org

  • Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA et al (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11:R46

    Article  Google Scholar 

  • Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ (2014) Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures. Int J Clini Pract 68 (12):1503–1507

    Article  CAS  Google Scholar 

  • Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J et al (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46:1372–1374

    Article  Google Scholar 

  • Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447–1461

    Article  CAS  Google Scholar 

  • Khanna PP, Gladue HS, Singh MK, FitzGerald JD, Bae S, Prakash S et al (2014) Treatment of acute gout: a systematic review. Semin Arthritis Rheum 44:31–38

    Article  CAS  Google Scholar 

  • Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE et al (2007) The impact of gout on work absence and productivity. Value Health 10:231–237

    Article  Google Scholar 

  • Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS et al (2010) Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 49:141–146

    Article  Google Scholar 

  • Martinon F (2010) Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 233:218–232

    Article  CAS  Google Scholar 

  • Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241

    Article  CAS  Google Scholar 

  • Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097

    Article  Google Scholar 

  • Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1

    Article  Google Scholar 

  • Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B et al (2011) TP53 mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 129:1532–1536

    Article  CAS  Google Scholar 

  • Neogi T (2011) Clinical practice. Gout N Engl J Med 364:443–452

    Article  CAS  Google Scholar 

  • Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM et al (2015) Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol 151:375–381

    Article  Google Scholar 

  • Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG (2004) Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10:308–314

    Article  Google Scholar 

  • Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69:1907–1912

    Article  CAS  Google Scholar 

  • Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V et al (2011a) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 13:R53

    Article  CAS  Google Scholar 

  • Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U et al (2011b) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70:1264–1271

    Article  CAS  Google Scholar 

  • Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839–1848

    Article  CAS  Google Scholar 

  • Schwarzer G (2007) meta: an R Package for meta-analysis, vol 7

  • Scire CA, Manara M, Cimmino MA, Govoni M, Salaffi F, Punzi L et al (2013) Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther 15:R101

    Article  Google Scholar 

  • So A (2008) Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 10:221

    Article  Google Scholar 

  • So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62:3064–3076

    Article  CAS  Google Scholar 

  • Suurmond R, van Rhee H, Hak T (2017) Introduction, comparison, and validation of meta-essentials: a free and simple tool for meta-analysis. Res Synth Methods 8:537–553

    Article  Google Scholar 

  • Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M et al (2013) Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis 72:694–700

    Article  CAS  Google Scholar 

  • Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P et al (2006) EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312–1324

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, 751019, Odisha, India

    Monalisa Jena, Amruta Tripathy & Rituparna Maiti

  2. Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India

    Archana Mishra

Authors
  1. Monalisa Jena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amruta Tripathy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Archana Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rituparna Maiti
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MJ concept and design, literature search, study selection and data collection, data extraction and management, data analysis and interpretation of data, critical revision of the manuscript for important intellectual content, and final approval of the manuscript. AT literature search, study selection and data collection, data extraction and management, and final approval of the manuscript. AM concept and design, data analysis and interpretation, drafting of the manuscript, and final approval of the manuscript. RM literature search, study selection and data collection, data extraction, critical revision of the manuscript for important intellectual content, and final approval of the manuscript.

Corresponding author

Correspondence to Rituparna Maiti.

Ethics declarations

Conflict of interest

None to declare.

Consent for publication

Authors are responsible for the correctness of the statements provided in the manuscript.

Availability of data and material

All data generated or analysed during this study are included in this published article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jena, M., Tripathy, A., Mishra, A. et al. Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis. Inflammopharmacol 29, 35–47 (2021). https://doi.org/10.1007/s10787-020-00753-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-020-00753-z

Keywords

Search

Navigation